Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference
Enochian BioSciences will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Enochian BioSciences will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Executive Vice Chair Dr. Mark Dybul will discuss advancements in the company's HIV, Hepatitis B, and Oncology platforms. The presentation will be accessible on-demand starting at 7 am Eastern. On March 10, Dr. Dybul and CFO Luisa Puche will engage in live one-on-one meetings with registered investors. For more details, attendees can visit the conference website.
Details
News Market Reaction – ENOB
The recorded move for ENOB in the trading session of this news was -4.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.
Executive Vice Chair Dr. Mark Dybul will provide an overview of the company’s progress, including its innovative HIV, Hepatitis B and Oncology platforms. The presentation will be available on-demand for conference attendees beginning at 7 am Eastern on Tuesday, March 9, 2021, and also will be available on the Enochian BioSciences website under the Investors/Media section in Events and Presentations.
On March 10, Dr. Dybul and Chief Financial Officer Luisa Puche will be participating in live, virtual one-on-one meetings with investors who are registered to attend the conference.
More information on the conference may be found at H.C. Wainwright’s conference website.
About Enochian BioSciences Inc.
Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS, HBV and Oncology.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.